Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study.


Journal Article

BACKGROUND: Advanced glycation endproducts are biologically active compounds that accumulate in disordered metabolism and normal aging. Carboxymethyl-lysine (CML), a ubiquitous human advanced glycation endproduct, has been associated with age-related conditions and mortality. Our objective was to ascertain the relationship between CML and geriatric outcomes (disability and frailty) in a large cohort of older men and women. METHODS: In 1996-1997, serum CML was measured in 3,373 Cardiovascular Health Study participants (mean age 78.1 ± 4.8 years). Disability, defined as difficulty in any of six activities of daily living, was assessed every 6-12 months for 14 years. Frailty was defined according to five standard criteria at the 1996-1997 visit. Cox proportional hazard models estimated the relationship between CML and incident disability (N = 2,643). Logistic regression models estimated the relationship between CML and prevalent frailty. RESULTS: Adjusting for multiple potential confounders, higher CML was associated with incident disability (hazard ratio per standard deviation [225 ng/mL] increase: 1.05, 95% CI 1.01-1.11). In men, odds of frailty increased with higher CML values (odds ratio = 1.30 per standard deviation, 95% CI 1.14-1.48), but the relationship was attenuated by adjustment for cognitive status, kidney function, and arthritis. CML was not associated with frailty in women. CONCLUSIONS: Higher serum CML levels in late life are associated with incident disability and prevalent frailty. Further work is needed to understand CML's value as a risk stratifier, biomarker, or target for interventions that promote healthy aging.

Full Text

Duke Authors

Cited Authors

  • Whitson, HE; Arnold, AM; Yee, LM; Mukamal, KJ; Kizer, JR; Djousse, L; Ix, JH; Siscovick, D; Tracy, RP; Thielke, SM; Hirsch, C; Newman, AB; Zieman, S

Published Date

  • June 2014

Published In

Volume / Issue

  • 69 / 6

Start / End Page

  • 710 - 716

PubMed ID

  • 24127427

Pubmed Central ID

  • 24127427

Electronic International Standard Serial Number (EISSN)

  • 1758-535X

Digital Object Identifier (DOI)

  • 10.1093/gerona/glt155


  • eng

Conference Location

  • United States